Kif18a inhibitor
Web9 sep. 2024 · We are excited to share new preclinical data from our KIF18A inhibitor program showing the ability of this compound to inhibit tumor growth in multiple different … WebAM-5308 is a potent mitotic kinesin KIF18A inhibitor. PC-49285: BTB-1. 86030-08-2: BTB-1 (KIF18A inhibitor BTB-1) is a selective and ATP-competitive mitotic kinesin KIF18A inhibitor, BTB-1 potently inhibits the ATPase activity of Kif18A with IC50 of 1.69 uM, does not inhibit other mitotic kinesins.
Kif18a inhibitor
Did you know?
Web7 apr. 2024 · By targeting KIF18A genetically and with novel small molecule inhibitors here we present data supporting KIF18A as therapeutic target in CIN tumors. – Methods and … WebBackground:KIF18A is a kinesin assisting chromosome congression and alignment during mitosis. It is nonessential in normal, euploid cell division but essential for a subset of aneuploid cancer cells with high chromosomal instability (CIN-high). KIF18A knockdown in these cells leads to mitotic arrest, cy- tostasis and cell death.
Web22 mrt. 2024 · Amgen is recruiting patients for a Phase I trial (NCT04293094) assessing the safety of its small molecule KIF18A inhibitor AMG 650 in up to 140 adults with … WebUS20240239441A1 - Kif18a inhibitors - Google Patents as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process...
Web23 okt. 2024 · Knocking down the expression of KIF3C inhibited proliferation of breast cancer cells via inducing G2/M phase arrest. 35 Reducing KIF22 ... Kif18A is involved in human breast carcinogenesis ... WebAMG650 (Sovilnesib) is an oral, first in class, selective small molecule inhibitor of KIF18A for treatment of advanced solid tumors. KIF18A is a mitotic kinesin motor protein that …
Web20 dec. 2024 · WO2024132648 - KIF18A INHIBITORS. Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical …
Web9 sep. 2024 · Lilly-Backed Volastra Enters Clinic with Amgen’s KIF18A Inhibitor. March 7, 2024. BioSpace. Volastra licenses Amgen molecule for chromosomally unstable cancers. March 7, 2024. C&EN. Armed with $60M series A and Lilly’s backing, Volastra enters clinic via Amgen cancer med. March 7, 2024. Fierce Biotech. Load More. matthew wackett homes englandWebPreclinical studies of KIF18A gene inactivation suggest its function can be dispensable for normal somatic cell division, 4,5 but cancer cells with chromosomal instability depend on … matthew waageWebMarch 07, 2024. Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline … matthew waack mdWeb4 sep. 2024 · KIF18A is overexpressed in various types of cancers, including but not limited to colon, breast, lung, pancreas, prostate, bladder, head, neck, cervix, and ovarian … matthew w abinanteWebTwo known KIF18A inhibitors exist; however, their function is either limited (BTB-1) or the efficacy remains to be publicly validated (Amgen). In this thesis, a screening protocol … here to grimsbyWebDescription: Selective and ATP-competitive Kif18A inhibitor Chemical Name: 4-Chloro-2-nitro-1- (phenylsulfonyl)benzene Purity: ≥99% (HPLC) Datasheet Citations Reviews Literature (2) Biological Activity Technical Data Solubility Calculators Datasheets References Biological Activity for BTB1 matthew wachsman mdWebKIF18A inhibitor 24 is a highly potent, in vivo active inhibitor of mitotic kinesin KIF18A with IC50 of 61 nM. Get Quotation Now * Please select Quantity before adding items. or Bulk Inquiry Bulk size, bulk discount! E-mail: [email protected] Tech Support: [email protected] Purity & Documentation Purity: >98% (HPLC) Biological Activity here to grow nursery